Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 25

1.

A mechanism for evasion of CTL immunity by altered O-glycosylation of HLA class I.

Yoneyama MS, Tobisawa Y, Hatakeyama S, Sato M, Tone K, Tatara Y, Kakizaki I, Funyu T, Fukuda M, Hoshi S, Ohyama C, Tsuboi S.

J Biochem. 2016 Dec 22. pii: mvw096. doi: 10.1093/jb/mvw096. [Epub ahead of print]

PMID:
28011817
2.

T1 high-grade bladder carcinoma outcome: the role of p16, topoisomerase-IIα, survivin, and E-cadherin.

Raspollini MR, Luque RJ, Menendez CL, Bollito E, Brunelli M, Martignoni G, Montironi R, Cheng L, Blanca A, Baroni G, Minervini A, Lopez-Beltran A.

Hum Pathol. 2016 Nov;57:78-84. doi: 10.1016/j.humpath.2016.06.022.

PMID:
27473264
3.

Role of galectin-3 in the pathogenesis of bladder transitional cell carcinoma.

Zeinali M, Adelinik A, Papian S, Khorramdelazad H, Abedinzadeh M.

Hum Immunol. 2015 Oct;76(10):770-4. doi: 10.1016/j.humimm.2015.09.036. Review.

PMID:
26429330
4.

Diagnostic and Prognostic Significance of Serum and Tissue Galectin 3 Expression in Patients with Carcinoma of the Bladder.

Gendy HE, Madkour B, Abdelaty S, Essawy F, Khattab D, Hammam O, Nour HH.

Curr Urol. 2014 Oct;7(4):185-90. doi: 10.1159/000365673.

5.

Galectin 3 for the diagnosis of bladder cancer.

El Gendy H, Madkour B, Abdelaty S, Essawy F, Khattab D, Hammam O, El Kholy A, Nour HH.

Arab J Urol. 2014 Jun;12(2):178-81. doi: 10.1016/j.aju.2013.10.004.

6.

Urinary IL-33 and galectin-3 increase in patients with interstitial cystitis/bladder pain syndrome (review).

Kochiashvili G, Kochiashvili D.

Georgian Med News. 2014 Jul-Aug;(232-233):12-5. Review.

PMID:
25214264
7.

Expression of the innate defense receptor S5D-SRCRB in the urogenital tract.

Miró-Julià C, Escoda-Ferran C, Carrasco E, Moeller JB, Vadekaer DF, Gao X, Paragas N, Oliver J, Holmskov U, Al-Awqati Q, Lozano F.

Tissue Antigens. 2014 Apr;83(4):273-85. doi: 10.1111/tan.12330.

PMID:
24641504
8.

Galectin-3 interactions with glycosphingolipids.

Collins PM, Bum-Erdene K, Yu X, Blanchard H.

J Mol Biol. 2014 Apr 3;426(7):1439-51. doi: 10.1016/j.jmb.2013.12.004.

PMID:
24326249
9.

Predictive factors for recurrence progression and cancer specific survival in high-risk bladder cancer.

Rodríguez Faba O, Palou J.

Curr Opin Urol. 2012 Sep;22(5):415-20. doi: 10.1097/MOU.0b013e328356ac20. Review.

PMID:
22825460
10.

A proposed score for assessing progression in pT1 high-grade urothelial carcinoma of the bladder.

Raspollini MR, Minervini A, Lapini A, Lanzi F, Rotellini M, Baroni G, Carini M.

Appl Immunohistochem Mol Morphol. 2013 May;21(3):218-27. doi: 10.1097/PAI.0b013e31825f3264.

PMID:
22820663
11.

MUC1 carrying core 2 O-glycans functions as a molecular shield against NK cell attack, promoting bladder tumor metastasis.

Suzuki Y, Sutoh M, Hatakeyama S, Mori K, Yamamoto H, Koie T, Saitoh H, Yamaya K, Funyu T, Habuchi T, Arai Y, Fukuda M, Ohyama C, Tsuboi S.

Int J Oncol. 2012 Jun;40(6):1831-8. doi: 10.3892/ijo.2012.1411.

12.

A novel strategy for evasion of NK cell immunity by tumours expressing core2 O-glycans.

Tsuboi S, Sutoh M, Hatakeyama S, Hiraoka N, Habuchi T, Horikawa Y, Hashimoto Y, Yoneyama T, Mori K, Koie T, Nakamura T, Saitoh H, Yamaya K, Funyu T, Fukuda M, Ohyama C.

EMBO J. 2011 Jun 28;30(15):3173-85. doi: 10.1038/emboj.2011.215.

13.

Galectin-3 expression is associated with bladder cancer progression and clinical outcome.

Canesin G, Gonzalez-Peramato P, Palou J, Urrutia M, Cordón-Cardo C, Sánchez-Carbayo M.

Tumour Biol. 2010 Aug;31(4):277-85. doi: 10.1007/s13277-010-0033-9.

PMID:
20401558
14.

[Galectin expression in urological cancer. Diagnostic, prognostic and therapeutic potential].

Waalkes S, Merseburger AS, Simon A, Serth J, Kuczyk MA.

Urologe A. 2010 Mar;49(3):387-91. German.

PMID:
20238481
15.

Proteomics analysis of bladder cancer exosomes.

Welton JL, Khanna S, Giles PJ, Brennan P, Brewis IA, Staffurth J, Mason MD, Clayton A.

Mol Cell Proteomics. 2010 Jun;9(6):1324-38. doi: 10.1074/mcp.M000063-MCP201.

16.

Decreased expression of galectin-3 predicts tumour recurrence in pTa bladder cancer.

Kramer MW, Kuczyk MA, Hennenlotter J, Serth J, Schilling D, Stenzl A, Merseburger AS.

Oncol Rep. 2008 Dec;20(6):1403-8.

PMID:
19020721
17.

Serum level of galectin-3 in human bladder cancer.

Sakaki M, Oka N, Nakanishi R, Yamaguchi K, Fukumori T, Kanayama HO.

J Med Invest. 2008 Feb;55(1-2):127-32.

18.

Gene-expression signature of adhesion/growth-regulatory tissue lectins (galectins) in transitional cell cancer and its prognostic relevance.

Langbein S, Brade J, Badawi JK, Hatzinger M, Kaltner H, Lensch M, Specht K, André S, Brinck U, Alken P, Gabius HJ.

Histopathology. 2007 Nov;51(5):681-90.

PMID:
17927590
19.

Protein profiling of bladder cancer using the 2D-PAGE and SELDI-TOF-MS technique.

Langbein S, Lehmann J, Harder A, Steidler A, Michel MS, Alken P, Badawi JK.

Technol Cancer Res Treat. 2006 Feb;5(1):67-72.

PMID:
16417404
20.

Immunohistochemical and in situ hybridization analysis of galectin-3, a beta-galactoside binding lectin, in the urinary system of adult mice.

Nio J, Takahashi-Iwanaga H, Morimatsu M, Kon Y, Iwanaga T.

Histochem Cell Biol. 2006 Jul;126(1):45-56.

PMID:
16404573
Items per page

Supplemental Content

Loading ...
Support Center